Covid-19
COVID-19 Medicines and Vaccines
Considering the relevant impact of the COVID-19 pandemic broadly on the society and on the health care system worldwide, it is crucial to expedite the development of effective measures to fight and prevent the spread of this virus, as well as to generate robust and interpretable evidence that would allow prompt definition of effective and safe therapeutics or vaccines against COVID-19.
This priority has been highlighted also by the European Medicines Agency in a press release that you find here.
This page intends to provide with an overview of the treatments, including vaccines, currently under evaluation or already approved at the European level.
COVID-19 treatments: authorisation status in Europe
In response to the global COVID-19 pandemic the European Medicines Agency is committed in expediting the development and approval of safe and effective treatments and vaccines. We offer here below an insight on the treatments' authorisation status in Europe.
Medicines undergoing evaluation
Vaccines undergoing evaluation
Authorised medicines
Authorised vaccines
A FOCUS ON RARE DISEASES
Due to the COVID-19 pandemic, people living with a rare disease are facing several difficulties in getting the needed treatments including lifesaving care, besides a higher risk of COVID-19 complications.
Ensuring them the access to COVID-19 vaccines, should be widely considered as a priority. Particular attention should be paid to different rare disease patients as they often suffer from comorbidities or take immunosuppressive therapies that might impair the vaccines action and response.
To address rare disease patients concerns and to guide the COVID-19 vaccines administration, some of the scientific societies and associations for rare diseases have already released guiding documents and FAQ sections for patients and healthcare professionals.
Data source: EMA website. Last update on 4 January 2022.
Do not hesitate to contact us for additional information.